Swedbank AB raised its stake in CVS Health Corporation (NYSE:CVS – Free Report) by 0.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,278,233 shares of the pharmacy operator’s stock after purchasing an additional 5,460 shares during the period. Swedbank AB owned about 0.18% of CVS Health worth $163,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also made changes to their positions in the company. TOWER TRUST & INVESTMENT Co lifted its stake in CVS Health by 0.8% in the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after acquiring an additional 132 shares during the last quarter. CYBER HORNET ETFs LLC increased its position in shares of CVS Health by 4.1% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after purchasing an additional 134 shares during the last quarter. LS Investment Advisors LLC lifted its position in shares of CVS Health by 3.9% during the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after purchasing an additional 135 shares during the last quarter. Moss Adams Wealth Advisors LLC lifted its position in shares of CVS Health by 4.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after purchasing an additional 135 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC grew its stake in shares of CVS Health by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after purchasing an additional 136 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.
CVS Health Stock Performance
Shares of NYSE CVS traded up $1.95 during midday trading on Tuesday, reaching $104.03. 991,825 shares of the company were exchanged, compared to its average volume of 8,472,365. The stock has a market cap of $132.74 billion, a P/E ratio of 45.84, a PEG ratio of 1.03 and a beta of 0.61. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $106.15. The stock has a fifty day simple moving average of $94.56 and a 200 day simple moving average of $83.31. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.
CVS Health News Roundup
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: Cantor Fitzgerald raised its price target on CVS Health to $110 from $100 and kept an overweight rating, signaling confidence in further upside and helping support the stock. Article Title
- Positive Sentiment: CVS is also drawing favorable attention for its improving momentum and turnaround narrative, with recent commentary highlighting margin expansion, a Q1 beat-and-raise, and expectations for stronger returns as the company executes on its strategic plan. Article Title
- Neutral Sentiment: The company announced it will hold its second-quarter 2026 earnings call on August 5, keeping investors focused on upcoming results and management commentary. Article Title
- Neutral Sentiment: CVS Health Foundation said it is investing $1 million in Hartford nonprofits, reinforcing its community-health brand and social impact efforts, though this is unlikely to move the stock on its own. Article Title
- Negative Sentiment: CVS Health agreed to a multi-million-dollar settlement tied to alleged false Medicaid and government program claims involving insulin pen dispensing, which adds legal and regulatory overhang. Article Title
- Negative Sentiment: The company also faced multiple recalls of CVS-branded medicated/hemorrhoidal wipes over child-safety concerns, which could pressure consumer trust and create modest reputational risk. Article Title
Insider Buying and Selling at CVS Health
In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Corporate insiders own 0.85% of the company’s stock.
Analysts Set New Price Targets
CVS has been the topic of a number of analyst reports. Mizuho raised their price target on CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Barclays upped their price objective on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Wall Street Zen raised CVS Health from a “hold” rating to a “buy” rating in a research report on Tuesday. Robert W. Baird increased their price target on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, Bank of America raised their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Twenty-one research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $102.60.
Check Out Our Latest Research Report on CVS
CVS Health Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
- Five stocks we like better than CVS Health
- 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers
- Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]
- Silicon Starvation: Amazon Feasts on Legacy GPUs
- GE Vernova’s Power Surge Turns the Grid Into an AI Trade
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
